Discussing how the first preventative therapy could delay type 1 diabetes and transform treatment.
What is Type 1 Diabetes?
Type 1 Diabetes (T1D) is an autoimmune disorder where the immune system selectively destroys the insulin-producing beta cells in the pancreas. This results in an absolute insulin deficiency and chronic hyperglycaemia, requiring lifelong insulin therapy. T1D typically progresses through 2 defined phases: the preclinical phase, characterised by the presence of autoantibodies but the absence of symptoms, and the clinical phase, where symptoms are present and a reliance on insulin therapy is established.
T1D generally manifests during childhood or adulthood, although onset can occur at any age. This disorder differs from Type 2 Diabetes (T2D) in that it is immune-mediated rather than lifestyle-related.
T1D is chronic and currently incurable, which makes breakthroughs like Teplizumab especially significant.
What is Teplizumab?
Teplizumab is a humanised anti-CD3 monoclonal antibody which has been designed to modulate the immune system in patients at risk of developing T1D. By selectively targeting CD3-positive T cells, Teplizumab reduces the autoimmune attack on pancreatic beta cells while preserving overall immune function.
The primary goal of Teplizumab is to delay the progression from the preclinical phase to the clinical phase, effectively postponing the onset of symptomatic T1D and reliance on insulin therapy.
The discovery of Teplizumab for T1D: Clinical trials
A crucial clinical trial in establishing teplizumab as a treatment for T1D was the TrialNet Prevention Study (TN10). This study recruited participants who were identified as being at a high risk for developing T1D, this identification was assessed based on the presence of multiple autoantibodies and other predictive biomarkers. These participants were given a 14 day course of Teplizumab, and their outcomes were monitored closely over several years.
The results showed:
- A 2 year median delay in disease onset, demonstrating significant prolonging of the preclinical phase.
- Approximately 36% of participants stayed disease-free or experienced a significantly delayed onset of more than 5 years.
- Patients maintained better endogenous insulin production compared to a placebo group, indicating functional beta-cell preservation.
These findings suggest that teplizumab can cause operational immune tolerance where there immune system becomes less aggressive towards pancreatic beta cells. The outcomes of this study not only demonstrates the potential of Teplizumab for the treatment of T1D but also provides evidence for early immunotherapeutic intervention for autoimmune disorders beyond T1D.
A breakthrough in T1D treatment
Up until now, treatment for T1D was primarily focussed on managing symptoms and preventing complications, however Teplizumab demonstrates a breakthrough in T1D treatment. As the first therapy shown to delay the onset of the clinical phase of T1D, teplizumab offers hope for a new approach to treatment. By extending the period before insulin dependance, teplizumab has the potential to improve quality of life, reduce the burden of daily disease management, and transform how we approach T1D treatment in the future.
Considerations in regards to Teplizumab
Despite the positive results, there are limitations which must be considered. Teplizumab is currently only approved for high-risk individuals who are identified through predictive markers, therefore it is not a solutions for all patients with T1D or at risk of T1D. Further limitations such as, long-term safety, accessibility, cost, and how it integrates with existing diabetes care remain key factors in determining the widespread effect of Teplizumab. Additionally whilst Teplizumab delays the onset of T1D, it currently does not provide a permanent cure, and patients may still eventually require insulin therapy. Nevertheless, delaying the disease onset can reduce the burden of daily disease management, decrease the risk of developing complications, and improve the overall quality of life for both patients and their families.
Beyond the direct clinical benefits, Teplizumab represents a shift in how the treatment of autoimmune disease is approached. It demonstrates that targeted immunotherapy can intervene before symptoms arise, highlighting an opportunity for similar preventative strategies in other autoimmune conditions; such as lupus and rheumatoid arthritis. This approach also highlights the importance of early detection and predictive medicine, potentially impacting the future methodology of autoimmune disease care.
Additionally, Teplizumab sparks optimism for the future of precision medicine. By tailoring treatment to individuals based on immune profiles and risk factors, clinicians could potentially personalise treatment plans to maximise efficacy and minimise unnecessary interventions. From this point of view, Teplizumab is not just a therapy, but also a beacon of hope for a new era in autoimmune disease prevention and treatment.
The future of Teplizumab
The approval of teplizumab is a significant development in T1D treatment.
In the future, ongoing research aims to:
- Evaluate the long term efficacy and safety.
- Expand the eligibility criteria to include a broader patient population.
- Assess cost-effectiveness to obtain wider accessibility.
This further research is required to maximise Teplizumab’s effectiveness, widen its accessibility, and move us towards a future where T1D is managed proactively rather than reactively.
Conclusion
Teplizumab represents advancement in T1D care, offering the first therapy shown to delay the onset of the clinical phase of the disease. It provides hope for both an improved quality of life and a shift from reactive to proactive disease management.
While the approval of Teplizumab is a significant milestone, further research is required to assess long-term outcomes, explore broader patient eligibility, and optimise implementation with existing healthcare systems and treatment methodology. This research will maximise the possibility that Teplizumab will have a real world impact, paving the way for preventative immunotherapy approaches in T1D and potentially other autoimmune diseases.
Teplizumab not only offers a new options for those at high-risk of T1D but also demonstrates a future where early interventions and disease prevention are central to medical care.
References
Herold, K. C., et al. (2019). An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine, 381(7), 603–613. https://www.nejm.org/doi/full/10.1056/NEJMoa1902226
Ramos, E. L., et al. (2023). Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2308743
U.S. Food and Drug Administration (FDA). (2023). FDA approves first drug that can delay onset of type 1 diabetes. https://www.fda.gov/media/164864/download
TrialNet. (2022). Teplizumab Prevention Study | Type 1 Diabetes TrialNet. https://www.trialnet.org/our-research/completed-studies/teplizumab
Keam, S. J. (2023). Teplizumab: First Approval. PubMed. https://pubmed.ncbi.nlm.nih.gov/36877454/